MedPath

Acute Normovolemic Hemodilution on ROTEM in Cardiac Surgery

Not Applicable
Completed
Conditions
Mitral Regurgitation
Mitral Stenosis
Tricuspid Regurgitation
Interventions
Procedure: Acute normovolemic hemodilution (ANH)
Drug: hydroxyethyl starch (HES 130/0.6)
Registration Number
NCT02502448
Lead Sponsor
Konkuk University Medical Center
Brief Summary

Impact of acute normovolemic hemodilution (ANH) using hydroxyethyl starch before initiating cardiopulmonary bypass (CPB) on whole blood viscoelastic profile after CPB has not been well established.

Patients undergoing cardiac surgery employing moderate hypothermic CPB (n=40) are randomly allocated into one of two groups: in Group-ANH(n=20), ANH is applied by using a balanced hydroxyethyl starch (HES 130/0.6); and in Group-C, ANH is not applied.

After weaning from CPB, intergroup differences of INTEM, EXTEM, FIBTEM and APTEM profiles are analyzed.

As a primary outcome, inter-group difference between maxiaml clot firmness of EXTEM will be determined at 10 min after ANH in Group-ANH and that at control.

Detailed Description

Background: Impact of acute normovolemic hemodilution (ANH) using hydroxyethyl starch before initiating cardiopulmonary bypass (CPB) on whole blood viscoelastic profile after CPB has not been well established.

Method: Patients undergoing cardiac surgery employing moderate hypothermic CPB (n=40) are randomly allocated into one of two groups: in Group-ANH(n=20), ANH is applied by using a balanced hydroxyethyl starch (HES 130/0.6); and in Group-C ANH is not applied.

Intergroup differences of INTEM, EXTEM, FIBTEM and APTEM profiles are analyzed. after anesthesia induction (control) and after weaning form CPB and protamine neutralization (after-CPB) in both groups. In Group-ANH, those are determined after ANH (after-ANH).

As a primary outcome, inter-group difference between maxiaml clot firmness of EXTEM is determined at 10 min after ANH in Group-ANH and that at control.

As secondary outcomes, intergroup differences of Hematocrit (Hct), Na+, K+, HCO3-, Ca2+, osmolarity, s-Cr are determined Intergroup difference of data at T2 are performed.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
70
Inclusion Criteria
  • patients undergoing cardiac surgery with cardiopulmonary bypass who signed written informed consent
Exclusion Criteria
  • preoperative renal failure requiring reran replacement therapy
  • preoperative liver disease
  • preoperative low cardiac output (EF < 50%)
  • Preoperative IABP application, Atrial fibrillation, Pacemaker,
  • contraindication for applying TEE
  • intraoperative withdrawal

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Acute normovolemic hemodilution groupAcute normovolemic hemodilution (ANH)patients undergoing cardiac surgery supposed to get aucte normovolemic hemodilution (ANH) before CPB
Acute normovolemic hemodilution grouphydroxyethyl starch (HES 130/0.6)patients undergoing cardiac surgery supposed to get aucte normovolemic hemodilution (ANH) before CPB
Primary Outcome Measures
NameTimeMethod
Maximal clot firmness of EXTEM10 min after completion of acute normovolemic hemodilution (ANH)

Maxiaml clot firmess (MCF) of EXTEM of rotational thromboleastometry

Secondary Outcome Measures
NameTimeMethod
Clot formation time of EXTEM10 min after completion of acute normovolemic hemodilution

Clot formation time of EXTEM of rotational thromboleastometry

A10 of FIBTEM10 min after completion of acute normovolemic hemodilution

A10 of FIBTEM of rotational thromboelastometry

Trial Locations

Locations (1)

Konkuk University Medical Center

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath